Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bioarctic AB
Industry Sector: HealthTechnology
CEO: Gunilla Christina Osswald, PhD
Number Of Employees: 107
Enterprise Value: $1,563,160,511
PE Ratio: -87.55
Exchange/Ticker 1: SSE:BIOA B
Exchange/Ticker 2: N/A
Latest Market Cap: $1,592,738,670
BioCentury | Apr 23, 2024
Deals
Deals report: Two Japanese pharmas set up local biotech incubator
Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more
BioCentury | Jul 7, 2023
Market Access
Biogen’s Viehbacher on Leqembi’s future
Full approval will unlock reimbursement and energize Alzheimer’s R&D, but the launch will be slow
BioCentury | Mar 1, 2023
Management Tracks
C4’s Adam Crystal to head R&D at Tango
Plus: new CFO at BioArctic and updates from Sutro, Korro, BioAtla, Claris, Akoya and more
BioCentury | Oct 7, 2022
Finance
3Q22 Wrap: always darkest before the dawn?
Biotech valuations continued to fall across all market cap tiers in 3Q22
BioCentury | Sep 28, 2022
Product Development
First solid win for amyloid could lead CMS to rethink controversial NCD
Full approval of Eisai’s lecanemab in Alzheimer’s could persuade CMS to re-assess requirements for class
BioCentury | May 11, 2022
Product Development
May 10 Quick Takes: ‘molecular machines’ company MOMA lands $150M series B
Plus GPCR play Domain raises $42M and updates from OncoHost, Eisai, UCB, Idorsia and more
BioCentury | Apr 21, 2022
Product Development
April 20 Quick Takes: AbbVie steps away from another alpha-synuclein program
Plus: Arcturus falls on efficacy data for COVID-19 vaccine, and updates from Dragonfly, I-Mab, Windtree and Oncomatryx
BioCentury | Jun 7, 2021
Finance
Aducanumab approval lifts shares of biotechs with Alzheimer’s programs
Biogen and Lilly together gain $36B in market cap
BioCentury | May 10, 2019
Financial News
New Eisai venture arm to focus on digital tech, dementia, cancer
BioCentury | Nov 16, 2018
Company News
AbbVie strengthens early stage neurology focus with Mission deal
Items per page:
1 - 10 of 23